© 2023 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2023 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
November 11, 2022
Dr Bardia provides his opinion on the current state of the ER+/HER2- treatment landscape and where elacestrant belongs in the current treatment paradigm.
November 10, 2022
Taking a closer look at the EMERALD trial, Dr Bardia shares key efficacy outcomes from the sub-group analyses 1) of patients with no prior chemotherapy and 2) comparing elacestrant to fulvestrant or AI.
November 09, 2022
Dr Bardia discusses the mechanism of action of elacestrant, how elacestrant compares to other SERDS, and introduces the EMERALD trial.
October 31, 2022
Dr Bardia talks about the role of biomarker testing and provides an overview of factors which may contribute to a clinician’s choice of treatment strategy for patients with ER+/HER- mBC.
Aditya Bardia, MD, MPH briefly explains metastatic ER+/HER2- breast cancer, and reviews existing treatment options for patients with ER+/HER2- mBC.
May 06, 2020
Aditya Bardia, MD, MPH, discusses the efficacy of sacituzumab govitecan in patients with triple-negative breast cancer.